S-1360 Shionogi-GlaxoSmithKline

Curr Opin Investig Drugs. 2003 Feb;4(2):206-9.

Abstract

Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. As of October 2002, phase II trials were ongoing and launch is expected in 2004/2005.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / metabolism
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Anti-HIV Agents / toxicity
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Furans
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Integrase Inhibitors / adverse effects
  • HIV Integrase Inhibitors / metabolism
  • HIV Integrase Inhibitors / pharmacology*
  • HIV Integrase Inhibitors / therapeutic use
  • HIV Integrase Inhibitors / toxicity
  • Humans
  • Triazoles

Substances

  • Anti-HIV Agents
  • Furans
  • HIV Integrase Inhibitors
  • S 1360
  • Triazoles